Buforin II
目录号 : GC68817Buforin II,来源于 buforin I,从亚洲蟾蜍 Bufo bufo gargarizans 胃中分离得到的蛋白,是一种高效的抗菌 (antimicrobial) 肽。Buforin II 对广谱的革兰氏阳性和革兰氏阴性细菌具有抗菌活性。
Cas No.:172998-24-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Buforin II, derived from buforin I, a protein isolated from the stomach of the Asian toad Bufo bufo gargarizans, is a potent antimicrobial peptide. Buforin II has antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria[1].
Buforin II inhibits A. baumanniiATCC 19606 and multiresistant strains with the similar MIC values of 8 mg/L[1].
Buforin II (intravenously a single dose, 1 mg/kg) has potent antibacterial activity that effectively reduces lethality and leads to a significant reduction in plasma endotoxin and cytokine concentrations in male Wistar rat model of sepsis[1].
Animal Model: | Male Wistar rats weighing 200 to 300 g with A. baumannii ATCC 19606[1] |
Dosage: | 1 mg/kg |
Administration: | Intravenously a single dose |
Result: | Reduced mortality by 40% in the treatment group and by 20% in the rifampicin (10 mg/kg) combination group. Reduced TNF, IL-6 and endotoxin plasma levels by 33%, 25% and 32%, respectively. |
Animal Model: | Male Wistar rats weighing 200 to 300 g with the multiresistant strain[1] |
Dosage: | 1 mg/kg |
Administration: | Intravenously a single dose |
Result: | Reduced mortality by 46.6% in the treatment group and by 20% in the rifampicin (10 mg/kg) combination group. Reduced TNF, IL-6 and endotoxin plasma levels by 46%, 20% and 28%, respectively. |
[1]. Oscar Cirioni, et al. Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. Crit Care Med. 2009 Apr;37(4):1403-7.
Cas No. | 172998-24-2 | SDF | Download SDF |
分子式 | C106H184N40O26 | 分子量 | 2434.85 |
溶解度 | H2O : 100 mg/mL (41.07 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.4107 mL | 2.0535 mL | 4.107 mL |
5 mM | 0.0821 mL | 0.4107 mL | 0.8214 mL |
10 mM | 0.0411 mL | 0.2054 mL | 0.4107 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。